Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to $16.7 million in the third quarter of 2023 from $12.4 million the year before, as operating expenses rose 19% to $19.1 million from $16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.
Current stock price: 127.32 pence, down 0.7%
12-month change: down 33%
Copyright 2023 Alliance News Ltd. All Rights Reserved.